📰 Ioscience News
Page 23 - Ioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ioscience. Real-time updates on events, politics, business and more.
February 15, 2022
Dr. Oliver Peoples, the CEO of Yield10 Bioscience explains the use of Camelina seed oil as a potential source of biofuel and discusses its implications in the transportation industry in a... | February 15, 2022
February 11, 2022
STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving Forward "During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical
February 11, 2022
San Diego- and Chengdu, China-based Ucello Therapeutics, a biotechnology startup which says it is developing universal CAR-T therapies, has raised $25M in a Series A financing round. The company said the funding was led by Matrix Partners Chin
February 9, 2022
Seoul [South Korea], February 9 (ANI/Global Economic): As the Omicron COVID-19 variant, which is now the most dominant strain in the world, rapidly spread in Korea, SK Bioscience also started developing Omicron-specific vaccines.
February 8, 2022
DJ Total Voting Rights Arix Bioscience PLC (ARIX) Total Voting Rights 08-Feb-2022 / 07:20 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible
February 5, 2022
Tech firms are leading the pack.
February 4, 2022
CINCINNATI _ Meridian Bioscience Inc. on Friday reported earnings of $15.3 million in its fiscal first quarter. The Cincinnati-based company said it had profit of 35 cents per... | February 4, 2022
February 2, 2022
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the controlKELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria")
February 2, 2022
DJ Arix Bioscience PLC: Clinical development update from portfolio company LogicBio Arix Bioscience PLC (ARIX) Arix Bioscience PLC: Clinical development update from portfolio company LogicBio 02-Feb-2022
February 1, 2022
Abcam to license in VHH phage library(1) from Twist, complementing in-house recombinant antibody capabilities Abcam to develop and commercialize antibodies for diagnostic and research use